Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 11/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 11/20 | 0.56 |
| ▸ | MLYCD | O95822 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581446 | 0.86 | HSD11B1 (0.44) | PTGS2HSD11B1 | |
| SCHEMBL15706951 | 0.84 | GABRA2 (0.55) | GABRA2GABRB2MLYCDPTGS2TGFBR1 | |
| SCHEMBL3572659 | 0.84 | GABRA2 (0.60) | GABRA2GABRB2PTGS2 | |
| SCHEMBL3587054 | 0.83 | GABRA2 (0.58) | GABRA2GABRB2MLYCDPTGS2TGFBR1 | |
| SCHEMBL13437658 | 0.81 | GABRA2 (0.83) | GABRA2GABRB2MLYCDPTGS2LMNA | |
| SCHEMBL2256856 | 0.81 | NR1H2 (0.64) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL13437646 | 0.79 | GABRA2 (0.83) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL3584615 | 0.78 | GABRA2 (0.61) | GABRA2GABRB2MLYCDPTGS2TGFBR1 | |
| SCHEMBL780788 | 0.78 | GABRA2 (0.49) | GABRA2GABRB2MLYCDPTGS2TGFBR1 | |
| SCHEMBL3576458 | 0.76 | PTGS2 (0.54) | PTGS2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2007002563-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | GABRA2 418/4885GABRB2 317/4885MLYCD 405/4885 |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | GABRA2 441/4885GABRB2 396/4885MLYCD 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.